Patents by Inventor Ralf Kleef

Ralf Kleef has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER
    Publication number: 20220041728
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 10, 2022
    Inventor: Ralf KLEEF
  • Low dose immune checkpoint blockade in metastatic cancer
    Patent number: 11161903
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: November 2, 2021
    Inventor: Ralf Kleef
  • IMMUNE CHECKPOINT THERAPY
    Publication number: 20210214428
    Abstract: Disclosed is (a) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Programmed Death-1 (PD-1) and/or an antibody or an antigen-binding protein portion thereof that specifically binds to and inhibits Programmed Death-L1 (PD-L1); (b) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4); and (c) Interleukin-2 (IL-2) for use in the treatment of a cancer patient, wherein the body core temperature of said patient is kept at a temperature of 39.0° C. to 40.5° C., preferably of 39.5° C. to 40.5° C. for at least 5 h per day for at least 4, preferably at least 5, consecutive days.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 15, 2021
    Inventor: Ralf KLEEF
  • IMMUNE CHECKPOINT THERAPY
    Publication number: 20190352382
    Abstract: Disclosed is (a) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Programmed Death-1 (PD-1) and/or an antibody or an antigen-binding protein portion thereof that specifically binds to and inhibits Programmed Death-L1 (PD-L1); (b) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4); and (c) Interleukin-2 (IL-2) for use in the treatment of a cancer patient, wherein the body core temperature of said patient is kept at a temperature of 39.0° C. to 40.5° C., preferably of 39.5° C. to 40.5° C. for at least 5 h per day for at least 4, preferably at least 5, consecutive days.
    Type: Application
    Filed: February 28, 2018
    Publication date: November 21, 2019
    Inventor: Ralf KLEEF
  • LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER
    Publication number: 20190292262
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventor: Ralf KLEEF
  • Low dose immune checkpoint blockade in metastatic cancer
    Patent number: 10358496
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: July 23, 2019
    Inventors: Tibor Bakács, Ralf Kleef
  • LOW DOSE IMMUNE CHECKPOINT BLOCKADE IN METASTATIC CANCER
    Publication number: 20170253655
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Application
    Filed: February 27, 2017
    Publication date: September 7, 2017
    Inventors: Tibor Bakács, Ralf Kleef